Radium-223 international early access program: results from the Spanish subset.

about

Radium-223 international early access program: results from the Spanish subset.

Item

http://www.wikidata.org/entity/Q47786425

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Radium-223 international early access program: results from the Spanish subset.

@en

Radium-223 international early access program: results from the Spanish subset.

@nl

type

Item

label

Radium-223 international early access program: results from the Spanish subset.

@en

Radium-223 international early access program: results from the Spanish subset.

@nl

prefLabel

Radium-223 international early access program: results from the Spanish subset.

@en

Radium-223 international early access program: results from the Spanish subset.

@nl

P1476

Radium-223 international early access program: results from the Spanish subset

@en

P2093

Aránzazu González Del Alba

http://www.w3.org/2001/XMLSchema#string

Begoña Mellado

http://www.w3.org/2001/XMLSchema#string

Begoña Pérez-Valderrama

http://www.w3.org/2001/XMLSchema#string

Cristina Moretones

http://www.w3.org/2001/XMLSchema#string

Daniel Castellano

http://www.w3.org/2001/XMLSchema#string

Jesús García Donas

http://www.w3.org/2001/XMLSchema#string

Joan Carles

http://www.w3.org/2001/XMLSchema#string

Josep R Germà

http://www.w3.org/2001/XMLSchema#string

José A Arranz

http://www.w3.org/2001/XMLSchema#string

José L Pérez-Gracia

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

P304

41-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0297

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29232987

http://www.w3.org/2001/XMLSchema#string